Abstract

Background Studies have reported benefit of oral therapy with the phosphodiesterase inhibitor, trapidil, in reducing restenosis after coronary angioplasty. Coronary stenting is associated with improved late outcome compared with balloon angioplasty, but significant neointimal hyperplasia still occurs in a considerable proportion of patients. The aim of this study was to investigate the safety and efficacy of trapidil 200mg in preventing in-stent restenosis.

Methods Patients with a single native coronary lesion requiring revascularization were randomized to placebo or trapidil at least 1h before, and continuing for 6 months after, successful implantation of a coronary Wallstent. The primary end-point was in-stent neointimal volume measured by three-dimensional reconstruction of intravascular ultrasound images recorded at the 6 month follow-up catheterization.

Results Of 312 patients randomized at 21 centres in nine countries, 303 (148 trapidil, 155 placebo) underwent successful Wallstent implantation, and 139 patients (90%) in the placebo group and 130 (88%) in the trapidil group had repeat catheterization at 26±2 weeks. There was no significant difference between trapidil and placebo-treated patients regarding in-stent neointimal volume (108·6± 95·6mm3vs 93·3±79·1mm3;P=0·16) or % obstruction volume (38±18% vs 36±21%;P=0·32), in angiographic minimal luminal diameter at follow-up (1·63±0·61mm vs 1·74±0·69mm;P=0·17), restenosis rate (31% vs 24%;P=0·24), cumulative incidence of major adverse cardiac events at 7 months (22% vs 20%;P=0·71) or anginal complaints (30% vs 24%;P=0·29).

Conclusion Oral trapidil 600mg daily for 6 months did not reduce in-stent hyperplasia or improve clinical outcome after successful Wallstent implantation and is not indicated for this purpose.

f1
Correspondence:Prof. P. W. Serruys, Erasmus Medical Center, Thoraxcenter Bd 408, Dr.Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

References

1
Serruys
PW
, de Jaegere P, Kiemeneij F. A comparison of Balloon-expandable -stent implantation with balloon angioplasty in patients with coronary artery disease.
N Engl J Med
 .
1994
;
331
:
489
–495
2
Fischman
DL
, Leon MB, Baim DS. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease.
N Engl J Med
 .
1994
;
331
:
496
–501
3
Foley
DP
, Rensing BJ, Pieper M. Clinical and quantitative angiographic outcomes following elective implantation of the self-expanding Wallstent for longer coronary artery lesions-Final results of the Wellstent Native study.
Int J Cardiovasc Interv
 .
1999
;
2
:
171
–179
4
Cercek
B
, Ebrahimi R, Dimayuga P, Khorsandi M, Forrester JS. Trapidil prevents rat smooth muscle cell proliferation in vitro and in vivo.
J Am Coll Cardiol
 .
1991
;
17
:
72A
5
Liu
MW
, Roubin GS, Robinson KA. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit.
Circulation
 .
1990
;
81
:
1089
–1093
6
Okamoto
S
, Inden M, Setsuda M, Konishi T, Nakano T. Effects of Trapidil a platelet derived growth factor antagonist, in preventing restenosis after percutaneous transcoronary angioplasty.
Am Heart J
 .
1992
;
123
:
1439
–1444
7
Maresta
A
, Balducelli M, Cantini L. Trapidil, a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty; results of the randomized, double-blind STARC Study.
Circulation
 .
1994
;
90
:
2710
–2715
8
Wittpoth
M
, Bönisch D, Schrör K. Trapidil inhibits RAF-1 kinase in vascular smooth muscle cells via activation of protein kinase A (PKA).
Circulation
 .
1997
;
96
:
I-558
9
Isner
JM
. Vascular remodelling. Honey, I think I shrunk the artery.
Circulation
 .
1994
;
89
:
2837
–2941
10
Circulation
 .
1999
;
100
:
799
–806
11
De Feyter
PJ
, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative angiography.
Circulation
 .
1999
;
100
:
1777
–1783
12
Li
W
, von Birgelen C, Hartlooper A. Semi-automated contour detection for volumetric quantification of intracoronary ultrasound. Computers in Cardiology. Washington: IEEE Computer Society Press; 1994. p. 277–80
13
Von Birgelen
C
, Di Mario C, Li W, Schuurbiers JC. Morphometric analysis in three-dimensional intracoronary ultrasound an in vivo and in vitro study performed with a novel system for contour detection of lumen and plaque.
Am Heart J
 .
1996
;
132
:
516
–527
14
Von Birgelen
C
, Airiian SG, de Feyter PJ, Foley DP, van der Giessen WJ, Serruys PW. Coronary Wallstents show significant late, post-procedural expansion despite implantation with adjunct high-pressure balloon inflatation.
Am J Cardiol
 .
1996
;
132
:
694
–696
15
Harder
S
, Thürmann P, Hellstern A, Benjaminov A. Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver chirrosis.
Br J Clin Pharmacol
 .
1996
;
42
:
443
–449
16
Serruys
PW
, Foley DP, de Feyter PJ. Quantitative coronary angiography in clinical practice. Dordrecht/Boston/London: Kluwer Academic Publishers; 1994.
17
Ohnishi
H
, Yamaguchi K, Shimada S, Suzucki Y, Kumagai A. A new approach to treatment of atherosclerosis and Trapidil as an antagonist to platelet-derived growth factor.
Life Sci
 .
1982
;
31
:
2595
–2602
18
Tiell
ML
, Sussmann I, Gordon PB, Sanders RN. Suppression of fibroblast proliferation in vitro and of neointimal hyperplasia in vivo by the triazolopyrimidine, Trapidil.
Artery
 .
1983
;
12
:
33
–50
19
Bönisch
D
, Weber AA, Withpoth M, Osinski M, Schrör K. Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase A.
Mol Pharmacol
 .
1998
;
54
:
241
–248
20
Galassi
AR
, Tamburino C, Nicosia A. A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation.
Catheter Cardiovasc Interv
 .
1999
;
46
:
162
–168
21
Ozaki
Y
, Keane D, Ruygrok P, vd Giessen WG, de Feyter P, Serruys PW. Six month clinical and angiographic outcome of the new less-shortening Wallstent in native coronary arteries.
Circulation
 .
1996
;
93
:
2114
–2120
22
Hanke
H
, Kamenz J, Hassenstein S. Prolonged proliferative response of smooth muscle cells after experimental intravascular stenting.
Eur Heart J
 .
1995
;
16
:
785
–793
23
Sabate
M
, Marijnissen JP, Carlier SG. Residual plaque burden, delivered dose, and tissue composition predict 6-month outcome after balloon angioplasty and beta-radiation therapy.
Circulation
 .
2000
;
101
:
2472
–2477

Comments

0 Comments